Brief report

BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome–positive leukemias

Dan Jones,1 Rajyalakshmi Luthra,1 Jorge Cortes,2 Deborah Thomas,2 Susan O’Brien,2 Carlos Bueso-Ramos,1 Seema Hai,1 Farhad Ravandi,2 Marcos de Lima,3 Hagop Kantarjian,2 and Jeffrey L. Jorgensen1

Departments of 1Hematopathology, 2Leukemia, and 3Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston

It remains unresolved how different BCR-ABL transcripts differentially drive lymphoid and myeloid proliferation in Philadelphia chromosome–positive (Ph+) leukemias. We compared BCR-ABL transcript type and level with kinase domain (KD) mutation status, genotype, and phenotype in 1855 Ph+ leukemias. Compared with e1a2/p190 BCR-ABL cases, de novo e13-e14a2/p210 Ph+ lymphoid leukemia more frequently showed CML-type background, had higher blast-normalized BCR-ABL transcript levels, and more frequent persistent BCR-ABL transcript in the absence of detectable lymphoblasts. Secondary lymphoid blast transformation of CML was exclusively due to e13/e14a2/p210 BCR-ABL but was associated, at a much higher level than p210 myeloid transformation, with acquisition of new KD mutations and/or Ph genomic amplification. In contrast, myeloid blast transformation was more frequently accompanied by new acquisition of acute myeloid leukemia-type chromosomal aberrations, particularly involving the EVII and RUNX1 loci. Therefore, higher kinase activity by mutation, transcriptional up-regulation or gene amplification appears required for lymphoid transformation by p210 BCR-ABL. (Blood. 2008;112:5190-5192)

Methods

All cases of fully characterized Ph+ leukemias seen at the University of Texas M. D. Anderson Cancer Center between the start of BCR-ABL RQ-PCR on July 17, 2001, and January 1, 2008, were included. A protocol under the first author (D.J.) for laboratory studies to perform molecular and laboratory studies to detect prognostic factors in leukemia was approved by the M. D. Anderson Cancer Center Institutional Review Board in accordance with the Declaration of Helsinki. Cases were diagnosed according to the criteria of the revised World Health Organization criteria, except that a 30% blast cutoff was used for secondary blast phase transformation of CML. Only acute leukemias with FCM characterization of the blasts were included. Nearly all patients presenting with Ph+ acute leukemias during this period received intensive multiagent chemotherapy and a tyrosine kinase inhibitor (usually imatinib mesylate and, more recently, dasatinib). Myeloid and lymphoid blasts were enumerated in posttreatment samples by 4-color flow cytometry (FCM), by comparison with the phenotype of normal marrow precursors using a standard MRD protocol assessing 2 × 105 cells with a panel with lymphoid, myeloid, and monocytic markers.

BCR-ABL RQ-PCR, kinase domain mutation DNA sequencing, BCR-ABL fluorescence in situ hybridization (FISH), and G-banded karyotyping were done as previously described. The RQ-PCR assay detects e1a2, e13a2, and e14a2 transcripts in a single tube and is normalized to ABL1, with BCR-ABL transcript type(s) determined by subsequent capillary electrophoretic separation of the fluorochrome-labeled products. This assay detects residual leukemia with up to 4- to 5-log decrease from baseline (newly diagnosed) levels. We note that 10% to 15% of e13a2/e14a2-expressing leukemias also express very low levels of the e1a2 transcript. False-negative results in diagnostic samples were extremely rare.
Table 1. Association of BCR-ABL transcript types and levels with pattern of Ph* leukemia

<table>
<thead>
<tr>
<th>Pattern of disease</th>
<th>e1a2 (p190)</th>
<th>e13a2/e14a2 (p210)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ph* ALL at presentation*</td>
<td>127†</td>
<td>41†</td>
<td></td>
</tr>
<tr>
<td>Normalized BCR-ABL transcript level (copies per μg RNA/blast count)</td>
<td>2313 (37-41 743)</td>
<td>3751 (224-57 569)</td>
<td>.015 (t test)</td>
</tr>
<tr>
<td>FC/MqPCR results match on FU</td>
<td>84/87 (97%)</td>
<td>15/28 (54%)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>BCR-ABL transcript detectable, 3 months</td>
<td>49/80 (61%)</td>
<td>27/30 (90%)</td>
<td>&lt;.005</td>
</tr>
<tr>
<td>BCR-ABL transcript detectable, 6 months</td>
<td>29/64 (45%)</td>
<td>24/30 (80%)</td>
<td>&lt;.005</td>
</tr>
<tr>
<td>Bilineal/biphenotypic Ph* acute leukemia¶</td>
<td>4</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Ph* AML at presentation†</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CML at presentation*</td>
<td>5**</td>
<td>1645</td>
<td></td>
</tr>
<tr>
<td>Progression to lymphoid blast crisis</td>
<td>0</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>Progression to myeloid blast crisis</td>
<td>2</td>
<td>69</td>
<td></td>
</tr>
</tbody>
</table>

ALL indicates acute lymphoid leukemia; AML, acute myeloid leukemia; CML, chronic myelogenous leukemia; FCM, flow cytometry; FU, follow-up sample after treatment; qPCR, BCR-ABL quantitative PCR.

*Two cases had cryptic BCR-ABL and are not included in column totals.
†Including 24 with one relapse, 20 with 2 or more relapses, 20 with persistent disease not initially responsive to therapy, and 6 who died during or before induction therapy.
‡Including 9 with one relapse, 9 with 2 or more relapses, 6 with persistent disease not initially responsive to therapy, and 2 who died during or before induction therapy.
¶Some of these, 7 cases were biphenotypic by FCM (5 myeloid/B-cell, 2 myeloid/T-cell phenotype), and 2 cases had apparent binealine lymphoid and myeloblasts.
|Blasts had monocytic and minimally differentiated phenotype, respectively.
IIBlasts were minimally differentiated in 2, myeloid in 12, myelomonocytic in 1, and megakaryocytic in 2.
§Two cases had cryptic BCR-ABL translocations not detected by PCR assay, 2 had e1a3 fusions, 2 had e19a2/p230, and 3 cases had e14a3 type. Translocations not detected by the quantitative PCR assay are not included in the column totals.
**Two cases had an altered transcript with truncation of the e1 exon, identified by DNA sequencing.

Results and discussion

Features distinguishing p190 and p210 Ph* acute leukemias

The p190/e1a2 BCR-ABL transcript was expressed in 127 of 168 (76%) Ph* lymphoid leukemias, in 4 of 9 (44%) biphenotypic/bilineal acute leukemias and in 2 of 17 (12%) Ph* AML. Mean presenting BCR-ABL levels normalized to blast counts were higher in e13/e14a2 ALL than in e1a2 cases (3751 vs 2313; P = .015, t test). Nineteen of the 41 (46%) e13/e14a2-expressing de novo ALL had features suggesting transformation from underlying CML, including background myeloid hyperplasia, abnormal megakaryocytic proliferation and/or basophilia, compared with only 3 of 120 (3%) e1a2-expressing cases (P < .001). At diagnosis or relapse, basophilia was seen in only 1 of 120 e1a2 lymphoid leukemias, compared with 10 of 41 e13/e14a2 cases. Results are summarized in Table 1.

Leukemic blast percentages quantified by MRD FCM and BCR-ABL transcript levels were compared after treatment among all Ph* lymphoid leukemias that had at least 3 sequential samples. Overall, cases with e13/e14a2 transcripts were more likely to have residual BCR-ABL transcript detectable at 3 months (90% vs 61%; P < .005) and 6 months (80% vs 45%; P < .002) after therapy initiation. FCM/RQ-PCR discordances were rare (3/87, 3%) in e1a2-expressing lymphoid leukemias, but common in e13/e14a2-expressing cases (13/28, 46%; P < .001). There were no differences in overall survival in e1a2 versus e13/e14a2 lymphoid leukemias (Figure 1), similar to some but not other studies which showed inferior or superior survival in different settings.

Features differentially associated with myeloid versus lymphoid blast transformation of p210-expressing CML

Expression of the e1a2 transcript characterized only 5 of 1659 (0.3%) cases presenting as chronic- or accelerated-phase CML, including 2 cases in which DNA sequencing demonstrated an altered e1a2 fusion transcript with partial in-frame deletions in the e1 exon. All of the 26 cases of CML that underwent secondary LBP and the 5 that underwent mixed myeloid/lymphoid binealine/biphenotypic transformation expressed e13/e14a2 transcripts. Two CMLs that rapidly underwent myeloblast blast transformation (MBP)
with a monocytic blast phenotype expressed e1a2, whereas all other cases with MBP expressed e13/e14a2.

Factors differentially associated with LBP and MBP in p210 CML were sought by comparing FISH for BCR-ABL gene copy number, frequency of BCR-ABL kinase domain mutation (KDM), and cytogenetic changes acquired at time of transformation. For MBP, 6 of 34 cases (18%) acquired a new KDM, 15 of 51 (29%) showed BCR-ABL amplification, and 60 of 68 (88%) had new karyotypic abnormalities, mostly frequently additional AML-type reciprocal chromosomal translocations [inv(3)(q21;q26) including the EVII locus in 13, t(3;21)(q26;q22) including the RUNX1 locus in 12, and inv(16)(p13q22)t(16;16) including the CBFB locus in 5] or chromosomal losses/gains, particularly del17p13/monosomy 17q, seen in 39 (57%) cases. With LBP, 17 of 21 (81%) cases acquired a new KDM (6 T315I, 4 Y253H, 2 F317L, and 1 each with F359C, F359V, E255K, M244V, and Q252H), 8 of 21 (38%) showed BCR-ABL amplification, and 7 of 24 (29%) had new clonal evolution, most frequently whole chromosome copy number changes (aneuploid).

We conclude that BCR-ABL transcript type and levels in association with pattern of secondary genetic changes can largely predict blast phenotype, with e1a2/p190 BCR-ABL expression nearly always exclusively driving lymphoid transformation, as supported by experimental studies. LBP of CML is unrelated to predict blast phenotype, with e1a2/p190 BCR-ABL expression association with pattern of secondary genetic changes can largely new clonal evolution, most frequently whole chromosome copy number changes (aneuploid).

References

BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome–positive leukemias

Dan Jones, Rajyalakshmi Luthra, Jorge Cortes, Deborah Thomas, Susan O'Brien, Carlos Bueso-Ramos, Seema Hai, Farhad Ravandi, Marcos de Lima, Hagop Kantarjian and Jeffrey L. Jorgensen